Pharmaceutical Economics and Policy
Pharmaceutical Economics and Policy is a research topic within Economics and Econometrics. Science Explorer counts 28k research works in it since 1950. 24.1% of them reached the world's top 10% most cited for their field and year.
This cluster of papers explores the economics of pharmaceutical research and development, focusing on topics such as drug development costs, generic drugs, pharmaceutical innovation, medicine prices, patent expiry, healthcare policies, market size, availability of medicines, and generic substitution.
- Drug Development Costs
- Generic Drugs
- Pharmaceutical Innovation
- Medicine Prices
- Patent Expiry
- Healthcare Policies
- Market Size
- Availability of Medicines
- Generic Substitution
- Pharmaceutical Industry
- Research works
- 28k fractional, since 1950
- In the world top 10%
- 6.7k per year above
- Top-10% rate
- 24.1% share of its works in the world top 10%
- Growth, 2013–17 → 2018–22
- +16% the tick is no change
Which countries lead Pharmaceutical Economics and Policy research?
By volume, the United States and India publish the most (1.4k and 470 works in 2022–2025).
By volume, 2022–2025
- 1 United States 1.4k works
- 2 India 470 works
- 3 United Kingdom 382 works
- 4 China 254 works
- 5 France 224 works
- 6 Germany 159 works
- 7 Canada 159 works
- 8 Italy 156 works
- 9 Spain 127 works
- 10 Australia 115 works
How concentrated that is
The same countries as shares of everything the list above accounts for. A node where two countries do two thirds of the work and one spread evenly across twelve read alike as a ranking and not at all alike here.
Shares of the rows listed above, not of the whole node.
Which institutions lead Pharmaceutical Economics and Policy research?
By volume in 2022–2025, Harvard University publishes the most Pharmaceutical Economics and Policy research, followed by Brigham and Women's Hospital and Johns Hopkins University.
By volume, 2022–2025
- 1 Harvard UniversityUnited States 38 works
- 2 Brigham and Women's HospitalUnited States 34 works
- 3 Johns Hopkins UniversityUnited States 23 works
- 4 University of North Carolina at Chapel HillUnited States 19 works
- 5 London School of Economics and Political ScienceUnited Kingdom 19 works
- 6 University of TorontoCanada 17 works
- 7 Yale UniversityUnited States 17 works
- 8 University of WashingtonUnited States 17 works
- 9 Peking UniversityChina 16 works
- 10 KU LeuvenBelgium 16 works
Who are the leading researchers in Pharmaceutical Economics and Policy?
The most-cited researchers publishing on Pharmaceutical Economics and Policy include David Moher, Martin McKee and Valentı́n Fuster.
- 1 David Moher Canada 38k citations
- 2 Martin McKee United Kingdom 5.4k citations
- 3 Valentı́n Fuster United States 5.4k citations
Ranked by citations received across their whole record, among researchers with at least three works on this topic.
Where is Pharmaceutical Economics and Policy research done?
The largest centres of Pharmaceutical Economics and Policy research in 2022–2025 are London (United Kingdom), Boston (United States), New York (United States) and Paris (France). Among places with at least 20 works in it, it is an unusually large share of all research in Sanaa and Silver Spring.
Largest cities, 2022–2025
- 1 London United Kingdom 150 works
- 2 Boston United States 99 works
- 3 New York United States 87 works
- 4 Paris France 75 works
- 5 Washington D.C. United States 72 works
- 6 Cambridge United States 64 works
- 7 Beijing China 60 works
- 8 Tokyo Japan 55 works
- 9 Moscow Russia 51 works
- 10 Baltimore United States 43 works
Where it is the local speciality
- SanaaYE · 26.7 works22×
- Silver SpringUS · 24.7 works22×
Location quotient: how much more of its research is in Pharmaceutical Economics and Policy than the world average.
Where is the best place to study Pharmaceutical Economics and Policy?
Among universities, judged by research, London School of Economics and Political Science, Harvard University and London School of Hygiene & Tropical Medicine score highest, combining excellence, specialisation, size, growth and international reach. Research strength is one signal when choosing where to study; it does not measure teaching.
One dot per university in the table below. The upper left is the interesting corner: small places doing unusually strong work.
| # | University | Score | Top 10% | Specialisation | Works | Growth |
|---|---|---|---|---|---|---|
| 1 | London School of Economics and Political ScienceUnited Kingdom | 74.1 | 53.5% | 14.6× | 19 | +24.7% |
| 2 | Harvard UniversityUnited States | 65.7 | 41.7% | 5.7× | 38 | +31.6% |
| 3 | London School of Hygiene & Tropical MedicineUnited Kingdom | 61.9 | 41.5% | 10.4× | 8 | +30.5% |
| 4 | University of Science and Technology of FujairahUnited Arab Emirates | 60.7 | 22.8% | 213.2× | 14 | — |
| 5 | Sana'a UniversityYemen | 56.2 | 23.1% | 32.4× | 14 | — |
| 6 | China Pharmaceutical UniversityChina | 55.8 | 48.1% | 9.6× | 11 | -70.0% |
| 7 | Medical University of SofiaBulgaria | 53.2 | 32.2% | 19.6× | 8 | +88.5% |
| 8 | JSS Academy of Higher Education and ResearchIndia | 52.3 | 17.6% | 13.5× | 8 | +504.2% |
| 9 | Johns Hopkins UniversityUnited States | 52.1 | 34.9% | 4.0× | 23 | +82.7% |
| 10 | University of Science and TechnologyYemen | 50.3 | 19.9% | 22.4× | 12 | -42.9% |
Universities only. Score blends excellence (30%), specialisation (25%), size (20%), growth (15%) and international reach (10%), 2015–2022; growth compares 2010–14 with 2015–19.
Is Pharmaceutical Economics and Policy research growing?
Output in 2018–2022 was 16% higher than in 2013–2017, peaking in 2024. The fastest-growing topics are Pharmaceutical Economics and Policy.
The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.
Which topics inside it are moving
Growth and decline on one axis around a shared zero. Two lists side by side hide the thing that matters: whether the growth dwarfs the decline, or the other way round.